Romark Global Pharma, LLC
Pharmaceutical product distributor
Based in PR
🤖
AI Overview
With $290K in lobbying spend across 10 quarterly filings, Romark Global Pharma, LLC is an active lobbying client. Their lobbying covers 1 issue area. Active from 2022 to 2024.
$290K
Total Spend
3
Years Active
1
Firms Hired
6
Lobbyists Deployed
1
Issues Lobbied
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2022 | $20K |
| 2023 | $270K |
| 2024 | $0 |
Issues Lobbied
Lobbying Firms
Lobbyists
What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Pharmacy
- •Issues regarding funding for Biomedical Advanced Research and Development Authority
- •Issues regarding Biomedical Advanced Research and Development Authority H.R. 2617, Consolidated Appropriations Act, 2023
- •Issues regarding Biomedical Advanced Research and Development Authority Covid-19 Therapeutics'
- •Issues regarding Biomedical Advanced Research and Development Authority Covid-19 Therapeutics' Pandemic All Hazards Prepardness Act
Related Analysis
Related Investigations
Big Pharma's $452M Lobbying Machine
How pharmaceutical companies spend hundreds of millions to influence health policy.
Federal Lobbying Statistics 2025
The definitive stats — $37.7B total, industry breakdowns, and trends.
What Is Lobbying? A Complete Guide
How lobbying works, who does it, and why it matters.
Similar Clients
Brownstein Hyatt Farber Schreck LLP Obo Romark Global Pharma, LLC
$0 total spend
Government of Puerto Rico
$2.9M total spend
Triple-s Management Corporation
$2.3M total spend
Financial Oversight and Management Board for Puerto Rico
$1.9M total spend
Medicaid and Medicare Advantage Products Association of Puerto Rico
$1.8M total spend
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.